Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC)

2019-10-24 12:49:22 | BioPortfolio


This is a randomized, double-blind, placebo controlled multicenter study.

A total of 700 patients will be included.

The study will include patients with primary sclerosing cholangitis (PSC) for daily intake of 40 mg simvastatin/placebo for 5 years. The aim is to study effect of prognosis of PSC by long term intake of simvastatin. Outcome measures are death, liver transplantation, cholangiocarcinoma or bleeding from esophageal varices.

Subjects will be randomized (1:1) between Simvastatin and placebo.

Study Design


Primary Sclerosing Cholangitis


Simvastatin 40mg, Placebo oral tablet


Not yet recruiting


Karolinska University Hospital

Results (where available)

View Results


Published on BioPortfolio: 2019-10-24T12:49:22-0400

Clinical Trials [3583 Associated Clinical Trials listed on BioPortfolio]

Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects

Determine the benefit of oral vancomycin therapy for Primary Sclerosing Cholangitis.

A Study of Oral Hymecromone to Treat Adults With Primary Sclerosing Cholangitis

Primary sclerosing cholangitis (PSC) is a chronic inflammatory disease of the biliary ducts in the liver resulting in destruction and fibrosis. PSC is associated with increased serum level...

Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)

The objectives of this qualitative study are to elicit concepts about symptoms that are important to patients with primary sclerosing cholangitis (PSC), as well as the key impacts of sympt...

A Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis

The purpose of this study is to determine whether curcumin, a drug and naturally-occurring plant compound, is safe and effective in the treatment of primary sclerosing cholangitis (PSC).

Safety, Tolerability, and Efficacy of GS-9674 in Non-Cirrhotic Adults With Primary Sclerosing Cholangitis (PSC-Phase 3)

The primary objective of this study is to evaluate whether GS-9674 reduces the risk of fibrosis progression among non-cirrhotic adults with primary sclerosing cholangitis (PSC).

PubMed Articles [10876 Associated PubMed Articles listed on BioPortfolio]

Distinct Disease Phenotype of Ulcerative Colitis in Patients With Coincident Primary Sclerosing Cholangitis: Evidence From a Large Retrospective Study With Matched Cohorts.

Primary sclerosing cholangitis is a classical extraintestinal manifestation in patients with ulcerative colitis. However, the impact of primary sclerosing cholangitis on the disease course is incomple...

Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: A GETAID multicentre cohort study.

Whether vedolizumab may be effective as a treatment for primary sclerosing cholangitis (PSC) in patients with inflammatory bowel disease (IBD) remains controversial.

Interferon-γ-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice.

Primary Sclerosing Cholangitis (PSC) is an idiopathic, chronic cholestatic liver disorder characterized by biliary inflammation and fibrosis. Increased numbers of intrahepatic interferon-γ- (IFNγ) p...

Validation, Clinical Utility and Limitations of the Amsterdam-Oxford Model for Primary Sclerosing Cholangitis.

Recently the Amsterdam-Oxford model (AOM) was introduced; a prognostic model to assess the risk of death and/or liver transplantation (LT) in primary sclerosing cholangitis (PSC). We aimed to validate...

Unique Phenotypic Characteristics and Clinical Course in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis: A Multicenter US Experience.

Ulcerative colitis (UC) associated with primary sclerosing cholangitis (PSC) is a rare phenotype. We aimed to assess patients with UC-PSC or UC alone and describe differences in clinical and phenotypi...

Medical and Biotech [MESH] Definitions

An integral membrane protein that is localized to TIGHT JUNCTIONS, where it plays a role in controlling the paracellular permeability of polarized cells. Mutations in the gene for claudin-1 are associated with Neonatal Ichthyosis-Sclerosing Cholangitis (NISCH) Syndrome.

Chronic inflammatory disease of the BILIARY TRACT. It is characterized by fibrosis and hardening of the intrahepatic and extrahepatic biliary ductal systems leading to bile duct strictures, CHOLESTASIS, and eventual BILIARY CIRRHOSIS.

A pharmaceutical preparation of ezetimibe and simvastatin that is used in the treatment of HYPERCHOLESTEROLEMIA and HYPERLIPIDEMIAS.

A branch of dentistry dealing with diseases of the oral and paraoral structures and the oral management of systemic diseases. (Hall, What is Oral Medicine, Anyway? Clinical Update: National Naval Dental Center, March 1991, p7-8)

Misunderstanding among individuals, frequently research subjects, of scientific methods such as randomization and placebo controls.

More From BioPortfolio on "Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC)"

Quick Search

Relevant Topic

Statins (or HMG-CoA reductase inhibitors) are a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, which plays a central role in the production of cholesterol in the liver. Increased cholesterol levels have been as...

Searches Linking to this Trial